Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Cancer Res Clin Oncol
    September 2025
  1. CHEN X, Kong R, Qi Y, Li L, et al
    MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:262.
    >> Share

  2. SHI Y, Zhao D, Xiao Z, Wang Y, et al
    The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.
    J Cancer Res Clin Oncol. 2025;151:252.
    >> Share

  3. KASTNER A, Kron A, Eilers L, Spier A, et al
    DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial.
    J Cancer Res Clin Oncol. 2025;151:244.
    >> Share

    August 2025
  4. WU X, Fang K, Huang W, Chen G, et al
    Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.
    J Cancer Res Clin Oncol. 2025;151:230.
    >> Share

  5. MANGUES-BAFALLUY I, Bernardez B, Martinez-Sesmero JM, Navarro-Ruiz A, et al
    Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study.
    J Cancer Res Clin Oncol. 2025;151:224.
    >> Share

    July 2025
  6. YANG J, Xu Q, Lu Y
    Decoding epithelial-fibroblast interactions in lung adenocarcinoma through single-cell and spatial transcriptomics.
    J Cancer Res Clin Oncol. 2025;151:221.
    >> Share

  7. YILDIZ O, Eryilmaz MK, Gurbuz AF, Kaya BE, et al
    Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience.
    J Cancer Res Clin Oncol. 2025;151:199.
    >> Share

    June 2025
  8. WANG D, Qiu J, Li R, Tian H, et al
    Development and interpretation of machine learning-based prognostic models for predicting high-risk prognostic pathological components in pulmonary nodules: integrating clinical features, serum tumor marker and imaging features.
    J Cancer Res Clin Oncol. 2025;151:190.
    >> Share

  9. ZHAO X, Fu W
    Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.
    J Cancer Res Clin Oncol. 2025;151:182.
    >> Share

  10. TAHERI P, Golden A
    A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights.
    J Cancer Res Clin Oncol. 2025;151:180.
    >> Share

    May 2025
  11. WU KW, Deng SY, Zhang XF, Zheng DW, et al
    Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.
    J Cancer Res Clin Oncol. 2025;151:158.
    >> Share

    April 2025
  12. WANG Z, Zeng Y, Jiang H, Luo C, et al
    Management strategies for primary lung carcinosarcoma: a case study and comprehensive literature review.
    J Cancer Res Clin Oncol. 2025;151:147.
    >> Share

  13. WU S, Hu C, Hu P, He W, et al
    RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting apoptosis.
    J Cancer Res Clin Oncol. 2025;151:138.
    >> Share

  14. SHIGETA N, Murakami S, Yamamoto K, Yokose T, et al
    Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:139.
    >> Share

    March 2025
  15. ZHAO QY, Liu WJ, Wang JG, Li H, et al
    Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism.
    J Cancer Res Clin Oncol. 2025;151:126.
    >> Share

  16. HUANG G, Chen L
    Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.
    J Cancer Res Clin Oncol. 2025;151:108.
    >> Share

    February 2025
  17. SHENG J, Jiao J, Yan N, Pan H, et al
    De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature.
    J Cancer Res Clin Oncol. 2025;151:82.
    >> Share

  18. WANG M, Zhang S, Yi D, Ou Y, et al
    Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:78.
    >> Share

  19. LI B, Wu Y, Zhang Y, Hu C, et al
    Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database.
    J Cancer Res Clin Oncol. 2025;151:68.
    >> Share

  20. WANG M, Liu H, Zhang R, Li R, et al
    Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review.
    J Cancer Res Clin Oncol. 2025;151:62.
    >> Share

  21. SUMINAGA K, Nomizo T, Yoshida H, Ozasa H, et al
    The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.
    J Cancer Res Clin Oncol. 2025;151:61.
    >> Share

    January 2025
  22. ENDO S, Imai H, Mouri A, Tsukamoto K, et al
    Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged >/= 75 years) with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:43.
    >> Share

  23. HU M, Meng X, Wang T, Wang Y, et al
    Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis.
    J Cancer Res Clin Oncol. 2025;151:38.
    >> Share

  24. GANESH SK, Devi CS
    Exploring the interactions of rapamycin with target receptors in A549 cancer cells: insights from molecular docking analysis.
    J Cancer Res Clin Oncol. 2025;151:31.
    >> Share

    December 2024
  25. DAI Q, Yao X, Zhang Y, Chai Q, et al
    CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;151:21.
    >> Share

    November 2024
  26. RISCHKE N, Kanbach J, Haug U
    Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.
    J Cancer Res Clin Oncol. 2024;150:503.
    >> Share

  27. LI S, Yuan T, Yuan J, Zhu B, et al
    Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy.
    J Cancer Res Clin Oncol. 2024;150:501.
    >> Share

  28. IBRULI O, Rose F, Beleggia F, Schmitt A, et al
    A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade.
    J Cancer Res Clin Oncol. 2024;150:496.
    >> Share

    October 2024
  29. LIU Y, Lin W, Gu Y, Lu C, et al
    Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.
    J Cancer Res Clin Oncol. 2024;150:481.
    >> Share

  30. MALMROS K, Kirova N, Kotarsky H, Carlsen D, et al
    3D cultivation of non-small-cell lung cancer cell lines using four different methods.
    J Cancer Res Clin Oncol. 2024;150:472.
    >> Share

  31. ZUO Y, Liu Q, Li N, Li P, et al
    Explainable (18)F-FDG PET/CT radiomics model for predicting EGFR mutation status in lung adenocarcinoma: a two-center study.
    J Cancer Res Clin Oncol. 2024;150:469.
    >> Share

  32. YANG L, Li M, Liu Y, Jiang Z, et al
    Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:453.
    >> Share

    September 2024
  33. WANG Q, Deng Z, Lu C, Chen L, et al
    A prospective study to compare the diagnostic accuracy of (99m)Tc-CNDG SPECT/CT and contrast-enhanced CT in staging of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:430.
    >> Share

  34. FANG Y, Wan J, Zeng Y
    Use machine learning to predict pulmonary metastasis of esophageal cancer: a population-based study.
    J Cancer Res Clin Oncol. 2024;150:420.
    >> Share

  35. GU G, Liu C, Zhu X, Yang Y, et al
    Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
    J Cancer Res Clin Oncol. 2024;150:413.
    >> Share

  36. KIM SH, Seong H, Lee J, Ahn HY, et al
    The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2024;150:409.
    >> Share

    August 2024
  37. LI X, Lu Y, Zhao J, Yu Y, et al
    Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:395.
    >> Share

  38. UHLENBRUCH M, Kruger S
    Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:394.
    >> Share

  39. NGUYEN OTD, Fotopoulos I, Nost TH, Markaki M, et al
    The HUNT lung-SNP model: genetic variants plus clinical variables improve lung cancer risk assessment over clinical models.
    J Cancer Res Clin Oncol. 2024;150:389.
    >> Share

    July 2024
  40. RATHOR A, Malik PS, Tanwar P, Khurana S, et al
    'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.
    J Cancer Res Clin Oncol. 2024;150:371.
    >> Share

  41. CHANG JX, Zhang M, Lou LL, Chu HY, et al
    KIS, a target of SOX4, regulates the ID1-mediated enhancement of beta-catenin to facilitate lung adenocarcinoma cell proliferation and metastasis.
    J Cancer Res Clin Oncol. 2024;150:366.
    >> Share

  42. CHEN H, Xu Y, Lin H, Wan S, et al
    A prognostic framework for predicting lung signet ring cell carcinoma via a machine learning based cox proportional hazard model.
    J Cancer Res Clin Oncol. 2024;150:364.
    >> Share

  43. ZHANG S, Guo C, Xu J, Qian P, et al
    Quantitative assessment of intertarget position variations based on 4D-CT and 4D-CBCT simulations in single-isocenter multitarget lung stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:359.
    >> Share

  44. FOTOPOULOS I, Nguyen OTD, Nost TH, Markaki M, et al
    Promising microRNAs in pre-diagnostic serum associated with lung cancer up to eight years before diagnosis: a HUNT study.
    J Cancer Res Clin Oncol. 2024;150:355.
    >> Share

  45. HE L, Chen H, Ruan B, He L, et al
    UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.
    J Cancer Res Clin Oncol. 2024;150:335.
    >> Share

    June 2024
  46. YEGHAIAN M, Tareco Bucho TM, de Bruin M, Schmitz A, et al
    Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
    J Cancer Res Clin Oncol. 2024;150:329.
    >> Share

  47. FENG Y, Qian R, Cui D, Luan J, et al
    Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.
    J Cancer Res Clin Oncol. 2024;150:312.
    >> Share

  48. LI Y, Wan Y, Yang X, Chen P, et al
    Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
    J Cancer Res Clin Oncol. 2024;150:290.
    >> Share

    May 2024
  49. HUANG BT, Lin PX, Luo LM, Wang Y, et al
    Incorporating the inflammation-related parameters enhances the performance of the nomogram for predicting local control in lung cancer patients treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:284.
    >> Share

  50. CHEN Z, Cai Y, Ou T, Zhou H, et al
    Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.
    J Cancer Res Clin Oncol. 2024;150:282.
    >> Share

  51. LI X, Wu D, Tang J, Wu Y, et al
    The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
    J Cancer Res Clin Oncol. 2024;150:271.
    >> Share

  52. WANG X, Xu Z, Zhao S, Song J, et al
    A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:269.
    >> Share

  53. DANG J, Xu G, Guo G, Zhang H, et al
    Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    J Cancer Res Clin Oncol. 2024;150:255.
    >> Share

  54. LI R, Tong R, Zhang JL, Zhang Z, et al
    Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:246.
    >> Share

  55. MENG X, Peng F, Yu S, Chi X, et al
    Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis.
    J Cancer Res Clin Oncol. 2024;150:228.
    >> Share

  56. CHEN Q, Cheng J, Wang L, Lv X, et al
    Primary lung cancer in children and adolescents.
    J Cancer Res Clin Oncol. 2024;150:225.
    >> Share

    April 2024
  57. TAMURA K, Okuma Y, Nomura S, Fukuda A, et al
    Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
    J Cancer Res Clin Oncol. 2024;150:216.
    >> Share

  58. BILGIN B, Kuralay Y, Yucel S
    Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
    J Cancer Res Clin Oncol. 2024;150:215.
    >> Share

  59. CHEN Y, Ji Y, Shen L, Li Y, et al
    High core 1beta1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:214.
    >> Share

  60. LIU W, Zhou D, Zhang L, Huang M, et al
    Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China.
    J Cancer Res Clin Oncol. 2024;150:205.
    >> Share

  61. WU X, Zhao X, Zhou C, Wei N, et al
    Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:188.
    >> Share

  62. HONG S, Lee JH, Heo JY, Suh KJ, et al
    Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    J Cancer Res Clin Oncol. 2024;150:186.
    >> Share

  63. WANG Y, Lyu D, Cheng C, Zhou T, et al
    Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    J Cancer Res Clin Oncol. 2024;150:185.
    >> Share

  64. ZHAO R, Guan X, Zhang P, Liu Y, et al
    Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
    J Cancer Res Clin Oncol. 2024;150:175.
    >> Share

  65. SAKASHITA M, Motoi N, Yamamoto G, Gambe E, et al
    An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections.
    J Cancer Res Clin Oncol. 2024;150:172.
    >> Share

    March 2024
  66. JIANG L, Yang P, Liu Y, Li J, et al
    BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    J Cancer Res Clin Oncol. 2024;150:162.
    >> Share

  67. BANAT M, Potthoff AL, Hamed M, Borger V, et al
    Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment.
    J Cancer Res Clin Oncol. 2024;150:136.
    >> Share

  68. GE Y, Zhan Y, He J, Li J, et al
    PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.
    J Cancer Res Clin Oncol. 2024;150:135.
    >> Share

  69. JU W, Lin L, Zhang Q, Lv X, et al
    GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.
    J Cancer Res Clin Oncol. 2024;150:126.
    >> Share

  70. SHIJUBOU N, Sumi T, Kubo T, Sasaki K, et al
    Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:125.
    >> Share

  71. MA M, Luo M, Liu Q, Zhong D, et al
    Influence of abdominal fat distribution and inflammatory status on post-operative prognosis in non-small cell lung cancer patients: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2024;150:111.
    >> Share

    February 2024
  72. KRIZOVA L, Benesova I, Zemanova P, Spacek J, et al
    Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:99.
    >> Share

  73. WANG Y, Dong A, Jin M, Li S, et al
    TEP RNA: a new frontier for early diagnosis of NSCLC.
    J Cancer Res Clin Oncol. 2024;150:97.
    >> Share

  74. NIU L, Wu H, Gao R, Chen L, et al
    Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
    J Cancer Res Clin Oncol. 2024;150:94.
    >> Share

  75. KURIBAYASHI T, Ohashi K, Nishii K, Ninomiya K, et al
    Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2024;150:89.
    >> Share

  76. ZHOU W, Yeerkenbieke G, Zhang Y, Zhou M, et al
    Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
    J Cancer Res Clin Oncol. 2024;150:90.
    >> Share

  77. XIA X, Ge Y, Ge F, Gu P, et al
    MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:88.
    >> Share

  78. FAN X, Zhang Q, Qin S, Ju S, et al
    CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:83.
    >> Share

  79. DU C, Tan L, Xiao X, Xin B, et al
    Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancer.
    J Cancer Res Clin Oncol. 2024;150:77.
    >> Share

  80. WU Y, Zhang J, Zhou W, Yuan Z, et al
    Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities.
    J Cancer Res Clin Oncol. 2024;150:74.
    >> Share

  81. CHENG X, Zhou J, Chen Y, Zhao Y, et al
    Patterns and trends of mortality from metastatic colorectal cancer in Shanghai, China from 2005 to 2021: a population-based retrospective analysis.
    J Cancer Res Clin Oncol. 2024;150:68.
    >> Share

    January 2024
  82. LIANG Y, Zhang X, Peng J, Liu J, et al
    Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses non-small cell lung cancer progression by targeting CRKL.
    J Cancer Res Clin Oncol. 2024;150:51.
    >> Share

  83. ZHANG H, Lin J, Yahaya BH
    Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:44.
    >> Share

  84. CUI Y, Lin J, Sun D, Zhang H, et al
    Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
    J Cancer Res Clin Oncol. 2024;150:45.
    >> Share

  85. WANG X, He J, Li J, Wu C, et al
    Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
    J Cancer Res Clin Oncol. 2024;150:43.
    >> Share

  86. ZHANG J, Han W, Guo J, Zhang C, et al
    Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:42.
    >> Share

  87. YUCE TH, Ak G, Metintas S, Dundar E, et al
    BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
    J Cancer Res Clin Oncol. 2024;150:38.
    >> Share

  88. HUANG BT, Wang Y, Lin PX
    Developing a clinical-radiomic prediction model for 3-year cancer-specific survival in lung cancer patients treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:34.
    >> Share

  89. LIU JJ, Shen WB, Qin QR, Li JW, et al
    Prediction of positive pulmonary nodules based on machine learning algorithm combined with central carbon metabolism data.
    J Cancer Res Clin Oncol. 2024;150:33.
    >> Share

  90. LU J, Feng Y, Guo K, Sun L, et al
    Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:25.
    >> Share

  91. ZHU L, Qin J
    Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
    J Cancer Res Clin Oncol. 2024;150:22.
    >> Share

  92. MENG X, Zhao X, Zhou B, Song W, et al
    FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:17.
    >> Share

  93. XU J, Chen H, Fan W, Qiu M, et al
    Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
    J Cancer Res Clin Oncol. 2024;150:7.
    >> Share

    December 2023
  94. BAI Y, Liu Y, Wu J, Miao R, et al
    CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
    J Cancer Res Clin Oncol. 2023;149:16827-16836.
    >> Share

  95. ZHANG W, He Z, Liang F, Gong J, et al
    Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
    J Cancer Res Clin Oncol. 2023;149:16763-16778.
    >> Share

  96. LU Y, Li Q, Xu L, Zheng Y, et al
    Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
    J Cancer Res Clin Oncol. 2023;149:16501-16510.
    >> Share

  97. YI M, Shi J, Tan X, Zhang X, et al
    Integration and deconvolution methodology deciphering prognosis-related signatures in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16441-16460.
    >> Share

  98. LIU W, Xia J, Du Q, Wang J, et al
    Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16365-16376.
    >> Share

  99. MENG X, Song W, Zhou B, Liang M, et al
    Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16311-16335.
    >> Share

  100. ZHANG J, Song L, Li G, Liang A, et al
    Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
    J Cancer Res Clin Oncol. 2023;149:17199-17213.
    >> Share

  101. SHIRAISHI S, Sugimoto M, Tokuuye K
    Salivary metabolites as novel independent predictors of radiation pneumonitis.
    J Cancer Res Clin Oncol. 2023;149:17559-17566.
    >> Share

    November 2023
  102. XU M, Hao Y, Shi Z, Song Z, et al
    Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490.
    >> Share

  103. XIONG Y, Gu F, Cui J, Liu Y, et al
    Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis.
    J Cancer Res Clin Oncol. 2023;149:15039-15053.
    >> Share

  104. LV H, Shao Y, Chen QS, Song WJ, et al
    A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature.
    J Cancer Res Clin Oncol. 2023;149:15287-15292.
    >> Share

  105. LIU J, Wei L
    Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:14577-14596.
    >> Share

  106. WANG Y, Yan C, Zhang C, Yu E, et al
    The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.
    J Cancer Res Clin Oncol. 2023;149:16069-16073.
    >> Share

  107. ZHOU J, Fang P, Liang Z, Li X, et al
    Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization.
    J Cancer Res Clin Oncol. 2023;149:15679-15686.
    >> Share

  108. ZHANG G, Guan H, Ning YL, Yao K, et al
    Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:15573-15588.
    >> Share

  109. MILJANIC M, Nwachukwu C, Rahimi A
    Definitive ablative stereotactic partial breast irradiation in early stage inoperable breast cancer.
    J Cancer Res Clin Oncol. 2023;149:15553-15559.
    >> Share

  110. CHANG Y, Xing H, Shang Y, Liu Y, et al
    Preoperative predicting invasiveness of lung adenocarcinoma manifesting as ground-glass nodules based on multimodal images of dual-layer spectral detector CT radiomics models.
    J Cancer Res Clin Oncol. 2023;149:15425-15438.
    >> Share

  111. GAO R, Gao Y, Zhang J, Zhu C, et al
    A nomogram for predicting invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules: incorporating subjective CT signs and histogram parameters based on artificial intelligence.
    J Cancer Res Clin Oncol. 2023;149:15323-15333.
    >> Share

  112. ZHANG L, Guan M, Zhang X, Yu F, et al
    Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:13553-13574.
    >> Share

    October 2023
  113. KUBO S, Kobayashi N, Matsumoto H, Somekawa K, et al
    Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 25. doi: 10.1007/s00432-023-05457.
    >> Share

  114. MOREIRA RS, da Silva MM, de Melo Vasconcelos CF, da Silva TD, et al
    Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 16. doi: 10.1007/s00432-023-05437.
    >> Share

  115. YIN T, Liu K, Shen Y, Wang Y, et al
    Alteration of serum bile acids in non-small cell lung cancer identified by a validated LC-MS/MS method.
    J Cancer Res Clin Oncol. 2023 Oct 10. doi: 10.1007/s00432-023-05434.
    >> Share

  116. LI C, Zhang Y, Xia Q, Hao B, et al
    Multi-omics analysis revealed the mitochondrial-targeted drug combination to suppress the development of lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 2. doi: 10.1007/s00432-023-05376.
    >> Share

    September 2023
  117. BRATOVA M, Skrickova J, Matusikova M, Hrabcova K, et al
    Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 28. doi: 10.1007/s00432-023-05431.
    >> Share

  118. WU R, Zhang B, He M, Kang Y, et al
    MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 20. doi: 10.1007/s00432-023-05404.
    >> Share

  119. ZHAO K, Xia C, Qiu M, Yang Z, et al
    Lobar or sublobar resection for early-stage second primary lung cancer
    J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05396.
    >> Share

  120. HUANG F, Cui J, Wan J, Yuan X, et al
    SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.
    J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05416.
    >> Share

  121. ZHANG Y, Xu H, Pi S, Tan H, et al
    The prognostic and immunological role of FKBP1A in an integrated muti-omics cancers analysis, especially lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 16. doi: 10.1007/s00432-023-05362.
    >> Share

  122. VOORN MJJ, Bastiaansen EMW, Schroder CD, van Kampen-van den Boogaart VEM, et al
    A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a feasible prehabilitation program before lung cancer surgery.
    J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05298.
    >> Share

  123. XIONG L, Zhu C, Lu Y, Chen M, et al
    Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 2. doi: 10.1007/s00432-023-05330.
    >> Share

  124. DONG H, Wang X, Qiu Y, Lou C, et al
    Establishment and visualization of a model based on high-resolution CT qualitative and quantitative features for prediction of micropapillary or solid components in invasive lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:10519-10530.
    >> Share

  125. JIANG B, Hu L, Dong D, Guo Z, et al
    TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    J Cancer Res Clin Oncol. 2023;149:10041-10052.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016